1415753-46-6

Basic information

• Product Name: 3-(2-hydroxybenzoyl)-9-methoxy-12b-methyl-6,7,12,12b-tetrahydro-indolo[2,3-a]quinolizine-1-carbonitrile
• Synonyms: 3-(2-hydroxybenzoyl)-9-methoxy-12b-methyl-6,7,12,12b-tetrahydro-indolo[2,3-a]quinolizine-1-carbonitrile
• CAS NO: 1415753-46-6
• Molecular Weight: 411.46
• Mol File: 1415753-46-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(2-hydroxybenzoyl)-9-methoxy-12b-methyl-6,7,12,12b-tetrahydro-indolo[2,3-a]quinolizine-1-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-hydroxybenzoyl)-9-methoxy-12b-methyl-6,7,12,12b-tetrahydro-indolo[2,3-a]quinolizine-1-carbonitrile(1415753-46-6)
• EPA Substance Registry System: 3-(2-hydroxybenzoyl)-9-methoxy-12b-methyl-6,7,12,12b-tetrahydro-indolo[2,3-a]quinolizine-1-carbonitrile(1415753-46-6)

Safety Data

• Hazardous Substances Data: 1415753-46-6(Hazardous Substances Data)

Upstream product

• 3589-73-9 methoxy-6-harmalan 
• 55593-86-7 3-(4-oxo-4H-chromen-3-yl)acrylonitrile 

Relevant articles and documents

An enantioselective inverse-electron-demand imino diels-alder reaction

The imino Diels-Alder reaction is an efficient method for the synthesis of aza-heterocycles. While different stereo- and enantioselective inverse-electron-demand imino Diels-Alder (IEDIDA) reactions have been reported before, IEDIDA reactions including electron-deficient dienes are unprecedented. The first enantioselective IEDIDA reaction between electron-poor chromone dienes and cyclic imines, catalyzed by zinc/binol complexes is described. The novel reaction provides a facile entry to a natural product inspired collection of ring-fused quinolizines including a potent modulator of mitosis. Copyright

Substituted indolo [2,3-a] quinolizines in the treatment of cancer

The present invention relates to novel substituted indolo [2,3-a] quinolizines of the general formula (I) and stereoisomeric forms thereof and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted indolo [2,3-a] quinolizines together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted indolo [2,3-a] quinolizines have been identified as useful for the prophylaxis and treatment of cancer by the induction of strong mitotic delays, chromosomal misalignments and mitotic tri- and multipolarization leading to cell cycle stop and apoptosis. Furthermore a synthesis for preparation of the substituted indolo [2,3-a] quinolizines is disclosed in the present invention.